SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76941.61
105.83 (0.14%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
91	Advanced Enzyme Technologies Ltd.	Q V PT	3,555 Small Cap	316.10 (-0.43%)	26.97	5.07	9.82	13.51	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
92	Windlas Biotech Ltd.	Q V PT	1,769 Small Cap	858.60 (0.18%)	26.62	3.44	16.15	15.34	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
93	Kovai Medical Center & Hospital Ltd.	Q V PT	6,411 Small Cap	5,946.75 (1.51%)	26.22	4.86	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
94	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,376.85 (0.23%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
95	Alivus Life Sciences Ltd.	Q V PT	13,876 Small Cap	1,120.45 (-0.89%)	24.58	4.16	9.20	6.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
96	Unichem Laboratories Ltd.	Q V PT	3,826 Small Cap	538.50 (-0.91%)	24.07	1.46	4.67	-173.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
97	FDC Ltd.	Q V PT	6,794 Small Cap	414.20 (-0.74%)	23.76	2.73	9.23	1.32	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
98	Alembic Pharmaceuticals Ltd.	Q V+ PT	16,009 Small Cap	821.70 (0.89%)	23.73	2.82	6.37	-8.79	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
99	3B Blackbio Dx Ltd.	Q V PT	1,112 Small Cap	1,290 (-0.39%)	22.54	4.07	46.29	132.12	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
100	Zydus Lifesciences Ltd.	Q V PT	1,10,523 Mid Cap	1,109.40 (0.13%)	21.93	4.25	13.52	14.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
101	Lupin Ltd.	Q V PT	1,10,189 Mid Cap	2,397.60 (-0.51%)	20.66	4.92	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
102	Fermenta Biotech Ltd.	Q V PT	1,307 Small Cap	443 (-0.23%)	20.33	3.11	3.85	-0.38	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
103	Anuh Pharma Ltd.	Q V PT	809 Small Cap	80.03 (-0.85%)	19.71	2.3	12.30	12.88	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
104	Aarti Drugs Ltd.	Q V PT	3,752 Small Cap	409.40 (-0.40%)	19.25	2.42	5.74	4.42	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
105	Fabtech Technologies Ltd.	Q V PT	661 Small Cap	152.35 (2.49%)	19.17	1.69	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
106	Indraprastha Medical Corporation Ltd.	Q V+ PT	3,382 Small Cap	368.65 (-0.08%)	18.42	4.57	10.30	29.46	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
107	Wanbury Ltd.	Q V+ PT	1,157 Small Cap	318.45 (-3.85%)	17.5	8.01	10.29	30.27	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
108	Krsnaa Diagnostics Ltd.	Q V+ PT	1,758 Small Cap	536.65 (-0.98%)	17.33	1.79	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
109	Syncom Formulations (India) Ltd.	Q V PT	1,240 Small Cap	13.08 (-0.83%)	16.31	3.01	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
110	Shalby Ltd.	Q V+ PT	1,783 Small Cap	161.50 (-2.15%)	15.79	1.43	12.52	25.39	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
111	Lincoln Pharmaceuticals Ltd.	Q V PT	1,163 Small Cap	581.95 (0.25%)	13.23	1.53	10.63	11.62	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
112	Natco Pharma Ltd.	Q V PT	16,606 Small Cap	924.15 (-0.32%)	11.71	1.8	18.26	32.57	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
113	Sun Pharma Advanced Research Company Ltd.	Q V+ PT	6,974 Small Cap	211 (-1.81%)	4.49	5.23	49.34	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
114	Nectar Lifesciences Ltd.	Q V PT	202 Small Cap	10.42 (0.00%)	N/A	0.35	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
115	Indoco Remedies Ltd.	Q V+ PT	2,287 Small Cap	244.10 (-1.47%)	N/A	2.08	6.54	-182.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
116	Panacea Biotec Ltd.	Q V+ PT	2,654 Small Cap	418.10 (-3.51%)	N/A	9.3	-8.75	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
117	Nephrocare Health Services Ltd.	Q V+ PT	6,853 Small Cap	688.45 (1.02%)	N/A	7.19	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
118	Solara Active Pharma Sciences Ltd.	Q V PT	2,439 Small Cap	502 (-0.71%)	N/A	1.91	-0.58	-134.64	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
119	Fischer Medical Ventures Ltd.	Q V PT	2,464 Small Cap	37.46 (-0.50%)	N/A	7.89	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
120	Sigachi Industries Ltd.	Q V+ PT	991 Small Cap	25.43 (-1.93%)	N/A	2.08	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Onesource Specialty	1,744.25	3.23%
Dr. Agarwals Health	487.60	2.53%
Metropolis Health.	592.35	2.53%
Fabtech Technologies	152.35	2.49%
Laurus Labs	1,745.85	1.84%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Acutaas Chemicals	3,109.85	-7.68%
Senores Pharmaceutic	1,318.70	-6.57%
Suven Life Sciences	298.90	-4.11%
Wanbury	318.45	-3.85%
Panacea Biotec	418.10	-3.51%

News about Top Pharma Companies in India

Jul, 2026

Panacea Biotec informs about disclosure

Pursuant to Regulation 30 read with Para B of Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI LODR Regulations’), Panacea Biotec has informed that the Company’s wholly owned subsidiary, Panacea Biotec Pharma (‘PBPL’), has received a Show Cause Notice dated July 23, 2026, from the office of the Assistant Commissioner, Goods and Services Tax (‘GST’), Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules, 2017 alleging total tax liability of ?4.06 Crore including interest, tax and penalty, on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite details as required under Regulation 30 of the SEBI LODR Regulations read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, and Industry Standards on Regulation 30 of SEBI LODR Regulations, are annexed as Annexure A.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Solara Active Pharma - Quaterly Results

The revenue zoomed 19.57% to Rs. 3816.00 millions for the quarter ended June 2026 as compared to Rs. 3191.50 millions during the corresponding quarter last year.Profit for the quarter ended June 2026 rises by 61.35% to Rs. 169.90 millions from Rs. 105.30 millions.OP of the company witnessed a marginal growth to 639.30 millions from 580.10 millions in the same quarter last year.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3816.00	3191.50	19.57	3816.00	3191.50	19.57	13689.80	12837.60	6.64
Other Income	19.20	9.80	95.92	19.20	9.80	95.92	58.90	91.40	-35.56
PBIDT	639.30	580.10	10.21	639.30	580.10	10.21	1925.70	2129.80	-9.58
Interest	202.30	239.00	-15.36	202.30	239.00	-15.36	942.40	1148.10	-17.92
PBDT	437.00	341.10	28.11	437.00	341.10	28.11	924.40	981.70	-5.84
Depreciation	267.10	235.80	13.27	267.10	235.80	13.27	996.80	992.50	0.43
PBT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
TAX	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
PAT	169.90	105.30	61.35	169.90	105.30	61.35	-72.40	-10.80	570.37
Equity	480.60	443.40	8.39	480.60	443.40	8.39	445.10	402.50	10.58
PBIDTM(%)	16.75	18.18	-7.83	16.75	18.18	-7.83	14.07	16.59	-15.21

Jul, 2026

Sanofi India informs about analyst meet

Sanofi India has informed that the Company will hold an investor / analysts call for an update on Unaudited Financial Results for the quarter and half year ended 30th June 2026, the details enclosed.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sanofi India informs about resignation of director

Pursuant to Regulation 30 of the Listing Regulations, Sanofi India has informed that Rachid Ayari (DIN:10408699) vide his letter dated 22nd July 2026, had conveyed his decision to step down from his current role as the Whole Time Director, Chief Financial Officer and Key Managerial Personnel of the Company with effect from the close of business hours on 30th September 2026, in view of his transition to another role within the Sanofi group. Accordingly, Rachid Ayari shall cease to be the Whole Time Director, Chief Financial Officer, Key Managerial Personnel and shall also cease to be Senior Management Personnel and member of the Risk Management Committee effective from the close of business hours on 30th September 2026. The Company places on record its sincere appreciation to Rachid Ayari for his valuable contributions, expert guidance, and dedicated assistance provided during his tenure with the Company. The Company is in the process of identifying a suitable candidate for the position of Chief Financial Officer, who will also be designated as a Key Managerial Personnel. The Company will inform the Stock Exchanges of the appointment in due course. The information required in terms of Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated 30th January 2026 is enclosed as ‘Annexure-I’ and letter received from Rachid Ayari is enclosed as ‘Annexure – II’.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Zydus Lifesciences gets nod to conduct Phase III trial of Desidustat in sickle cell disease

The trial will enrol 164 patients diagnosed with the disease

Jul, 2026

Wanbury informs about updates

Further to its letter dated 20th July, 2026, Wanbury has informed that a routine current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the company's facility at Tanuku, West Godavari District, Andra Pradesh during the period from July 13, 2026 to July 17, 2026. At the conclusion of the inspection, the USFDA has issued a Form 483 with six observations. The Company will respond to these observations to FDA within the stipulated time. The relevant disclosures as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular HO/ 49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are provided in Annexure - I.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Biocon Ltd.	71,063 Crore
2	Jubilant Pharmova Ltd.	15,582 Crore
3	Healthcare Global Enterprises Ltd.	10,110 Crore
4	Onesource Specialty Pharma Ltd.	19,375 Crore
5	Senores Pharmaceuticals Ltd.	6,500 Crore
6	Park Medi World Ltd.	12,060 Crore
7	Fortis Healthcare Ltd.	71,140 Crore
8	Aster DM Quality Care Ltd.	70,000 Crore
9	Wockhardt Ltd.	30,311 Crore
10	Rubicon Research Ltd.	25,860 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,629	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,746	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,932	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,551	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,294	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,347	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,586	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,398	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,893	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,145	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,109	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,983	4,73,509	41.25	5.67	23.65	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Panacea Biotec informs about disclosure

Solara Active Pharma - Quaterly Results

Sanofi India informs about analyst meet

Sanofi India informs about resignation of director

Zydus Lifesciences gets nod to conduct Phase III trial of Desidustat in sickle cell disease

Wanbury informs about updates

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.